HIV vaccine(NuGenerex Immuno-Oncology, Inc.)(HIV vaccine(NuGenerex Immuno-Oncology, Inc.))

概要

基本信息

药物类型

预防性疫苗

别名

AE-H vaccine、HIV vaccine

靶点-

作用方式

刺激剂

作用机制

辅助诱导T-淋巴细胞刺激剂

治疗领域

免疫系统疾病感染泌尿生殖系统疾病

在研适应症

HIV感染

非在研适应症-

原研机构

NuGenerex Immuno-Oncology, Inc.

在研机构

NuGenerex Immuno-Oncology, Inc.

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

1

项与 HIV vaccine(NuGenerex Immuno-Oncology, Inc.) 相关的临床试验

NCT01320176

/ Completed临床1期

An Open-label, Phase I, Dose-escalation and Safety Study of Two Intramuscular Injections of a Dose of 2.9 Log or 4 Log CCID50 of the Recombinant HIV I Clade B Measles Vaccine Vector in Healthy Adults.

This study aimed to evaluate the safety and reactogenicity of two intramuscular injections of two different dosages of an investigational clade B HIV vaccine.

开始日期2010-10-01

申办/合作机构

Institut Pasteur

100 项与 HIV vaccine(NuGenerex Immuno-Oncology, Inc.) 相关的临床结果

登录后查看更多信息

100 项与 HIV vaccine(NuGenerex Immuno-Oncology, Inc.) 相关的转化医学

登录后查看更多信息

100 项与 HIV vaccine(NuGenerex Immuno-Oncology, Inc.) 相关的专利（医药）

登录后查看更多信息

1

项与 HIV vaccine(NuGenerex Immuno-Oncology, Inc.) 相关的文献（医药）

2021-11-01·Journal of Applied Physiology3区 · 医学

Aerobic exercise with blood flow restriction causes local and systemic hypoalgesia and increases circulating opioid and endocannabinoid levels

3区 · 医学

Article

作者: Grant, Ian ; Patterson, Stephen David ; Hughes, Luke

We have shown that performing blood flow restriction (BFR) during low-intensity aerobic exercise can trigger local and systemic hypoalgesia, which is not typically observed with this intensity of exercise. High-pressure BFR triggers greater and comparable hypoalgesia than high-intensity aerobic exercise in the exercising limbs and remote areas of the body, respectively. Performing BFR during low-intensity aerobic exercise activates the opioid and endocannabinoid systems, providing novel insight into potential mechanisms of hypoalgesia with BFR exercise

100 项与 HIV vaccine(NuGenerex Immuno-Oncology, Inc.) 相关的药物交易

登录后查看更多信息